Michał Ciesielczyk
Research Subjects
Research Interests
Michał Ciesielczyk has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Jarosław Damian Kasprzak
Medical University of Lodz
8 shared publications - Jarosław Drozdz
Department of Cardiology, Medical University of Lodz, Lodz, Poland
8 shared publications - Michał Plewka
II Katedra i Klinika Kardiologii, Uniwersytet Medyczny w Łodzi, Łódź
8 shared publications Maria Krzemińska-Pakuła
7 shared publicationsKarina Wierzbowska
2 shared publicationsMarcin Zwierzak
2 shared publications
Latest Publications
- 1 April 2004
- Vol. 59 (2) , 211-2
Usefulness of contrast enhancement for the echocardiographic quantitative assessment of aortic stenosis.
- 1 April 2004
- Vol. 59 (2) , 211-2
Usefulness of contrast enhancement for the echocardiographic quantitative assessment of aortic stenosis.
- 1 February 2003
- Vol. 19 (2) , 135-9
Predictors of long term outcome in medically treated patients with unstable angina.
The choice of invasive or noninvasive strategy for low risk patients with unstable angina is a challenge. To investigate the impact of clinical factors on adverse outcomes in patients receiving successful medical treatment and referred from the hospital without invasive procedures. The study group consisted of 166 patients (54% men, age 63+/-11 years) who were discharged symptom free after pharmacological treatment of unstable angina. The authors analyzed demographic, clinical, electrocardiographic, echocardiographic and laboratory parameters. During two years of follow-up, the mortality rate was 4.2%. A composite end point (coronary disease hospitalization, recurrent unstable angina, necessity for revascularization or death) occurred in 99 patients (60%). In multivariate logistic regression, the Canadian Cardiovascular Society (CCS) class (P=0.015) and the left ventricular ejection fraction (P=0.01) were independently predictive for the adverse events. A scoring system was proposed for simple risk stratification, with one point assigned to the patient for CCS class III or IV and left ventricular ejection fraction below 40%, thus yielding a score in the range of 0 to 2. The adverse event rates for total scores of 0, 1 and 2 were 37%, 64% and 86%, respectively. Uncomplicated follow-up in medically treated patients with unstable angina is rare. Patients with CCS class III and IV or left ventricular ejection fraction below 40% have particularly high rates of recurrent ischemia.
- 1 February 2003
- Vol. 19 (2) , 135-9
Predictors of long term outcome in medically treated patients with unstable angina.
The choice of invasive or noninvasive strategy for low risk patients with unstable angina is a challenge. To investigate the impact of clinical factors on adverse outcomes in patients receiving successful medical treatment and referred from the hospital without invasive procedures. The study group consisted of 166 patients (54% men, age 63+/-11 years) who were discharged symptom free after pharmacological treatment of unstable angina. The authors analyzed demographic, clinical, electrocardiographic, echocardiographic and laboratory parameters. During two years of follow-up, the mortality rate was 4.2%. A composite end point (coronary disease hospitalization, recurrent unstable angina, necessity for revascularization or death) occurred in 99 patients (60%). In multivariate logistic regression, the Canadian Cardiovascular Society (CCS) class (P=0.015) and the left ventricular ejection fraction (P=0.01) were independently predictive for the adverse events. A scoring system was proposed for simple risk stratification, with one point assigned to the patient for CCS class III or IV and left ventricular ejection fraction below 40%, thus yielding a score in the range of 0 to 2. The adverse event rates for total scores of 0, 1 and 2 were 37%, 64% and 86%, respectively. Uncomplicated follow-up in medically treated patients with unstable angina is rare. Patients with CCS class III and IV or left ventricular ejection fraction below 40% have particularly high rates of recurrent ischemia.
- 1 February 2002
- Vol. 57 (1) , 44-6
Echocardiographic identification of resting perfusion defects using bolus administration of Levovist and power contrast imaging.
- 1 February 2002
- Vol. 57 (1) , 44-6
Echocardiographic identification of resting perfusion defects using bolus administration of Levovist and power contrast imaging.
- 1 February 2002
- Vol. 57 (1) , 66-7
Prognostic value of colour Doppler echocardiography in patients after myocardial infarction--2-year follow-up.
- 1 February 2002
- Vol. 57 (1) , 66-7
Prognostic value of colour Doppler echocardiography in patients after myocardial infarction--2-year follow-up.
- 1 February 2002
- Vol. 57 (1) , 68-9
Tissue Doppler echocardiography during low-dose dobutamine infusion in patients with ischaemic and idiopathic dilated cardiomyopathy.
- 1 February 2002
- Vol. 57 (1) , 68-9
Tissue Doppler echocardiography during low-dose dobutamine infusion in patients with ischaemic and idiopathic dilated cardiomyopathy.
- 1 January 2002
- Vol. 59 (8) , 658-62
Clinical application of 3-dimensional echocardiography--a 3-year single center experience.
3-dimensional echocardiography (3DE) is a novel and rapidly evolving echocardiographic technique. Theoretically, 3DE should be helpful in difficult cases when 2-dimensional echocardiography (2DE) cannot deliver required information due to complex spatial relationships in diseased heart of inability to obtain a desired cross-sectional view. Accurate quantification is another potential benefit of 3DE. In this study we present our 3-year experience in 3DE applied to selected clinical population. Retrospective analysis of our database provided data of 204 3DE studies performed with TomTec Echoscan 3.1 using rotational device from transthoracic or transesophageal window. A total of 474 3DE acquisitions were performed. The main indications for 3DE were: Assessment of left ventricular function (51);--valvular heart disease (47), assessment of thoracic aorta (36), congenital anomalies (36) and cardiac masses (22). Quality of resulting 3D image was graded as 0--bad, 1--satisfactory, 2--good, 3--demo. Average quality of reconstruction was 2.1 +/- 0.8, with 73% of interpretable (score 2-3) studies. Compared to 2DE, additional morphologic or quantitative information was obtained in 47% of patients, including: left ventricular function assessment (41%); valvular heart disease (40%); assessment of descending aorta assessment (31%); congenital anomalies (64%); and cardiac masses (64%). 3DE can be incorporated into the routine diagnostic pathway with a high feasibility rate. 3DE is a valuable tool in clinically indicated cases by providing additional qualitative or quantitative information in 47% of cases.
- 1 January 2002
- Vol. 59 (8) , 658-62
Clinical application of 3-dimensional echocardiography--a 3-year single center experience.
3-dimensional echocardiography (3DE) is a novel and rapidly evolving echocardiographic technique. Theoretically, 3DE should be helpful in difficult cases when 2-dimensional echocardiography (2DE) cannot deliver required information due to complex spatial relationships in diseased heart of inability to obtain a desired cross-sectional view. Accurate quantification is another potential benefit of 3DE. In this study we present our 3-year experience in 3DE applied to selected clinical population. Retrospective analysis of our database provided data of 204 3DE studies performed with TomTec Echoscan 3.1 using rotational device from transthoracic or transesophageal window. A total of 474 3DE acquisitions were performed. The main indications for 3DE were: Assessment of left ventricular function (51);--valvular heart disease (47), assessment of thoracic aorta (36), congenital anomalies (36) and cardiac masses (22). Quality of resulting 3D image was graded as 0--bad, 1--satisfactory, 2--good, 3--demo. Average quality of reconstruction was 2.1 +/- 0.8, with 73% of interpretable (score 2-3) studies. Compared to 2DE, additional morphologic or quantitative information was obtained in 47% of patients, including: left ventricular function assessment (41%); valvular heart disease (40%); assessment of descending aorta assessment (31%); congenital anomalies (64%); and cardiac masses (64%). 3DE can be incorporated into the routine diagnostic pathway with a high feasibility rate. 3DE is a valuable tool in clinically indicated cases by providing additional qualitative or quantitative information in 47% of cases.